trending Market Intelligence /marketintelligence/en/news-insights/trending/3VoEqvJwrorUGg-QZY3O5Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Summa Equity buys majority stake in Olink Proteomics

StreetTalk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk – Episode 69: Banks left with pockets full of cash and few places to go

Street Talk Episode 68 - As many investors zig away from bank stocks, 2 vets in the space zag toward them

Street Talk Episode 66 - Community banks tap the debt markets while the getting is good

Summa Equity buys majority stake in Olink Proteomics

Summa Equity purchased Sweden-headquartered life sciences company Olink Proteomics AB, which has developed technology for human biomarker discovery.

Under the deal, the private equity firm will become the company's majority shareholder, while its founder Ulf Landegren and the management team will continue as stockholders.

Moelis & Co. LLC served as financial adviser to Summa, White & Case was its legal adviser, LEK Consulting was its commercial adviser and KPMG was its accounting adviser. J.P. Morgan Securities LLC acted as financial adviser to Olink, while Wiggin, Dana LLP and Lindahl were its legal advisers.